Speaker Profile

Ph.D., Director, Analytics Product Management, Medidata Solutions

Ana Oromendia has spent her career at the interplay of life sciences and technology, devoted to getting better treatments to the right patients at the right time. In her current role, she leads a team-building tools and technology to bring Omic data and analysis to Clinical Development, quickly and effectively enabling every clinical trial to collect Multi-Omic data and providing tools to ensure that all of the data is effectively analyzed. She has a background in experimental and analysis design of large 'omic datasets in large multidisciplinary scientific collaborations and the development of genetic tests and supporting software solutions. At Acorn AI a Medidata Company, Ana is part of a team creating analytical tools to improve the efficiency and rigor in the therapeutic development process and with the ultimate goal of getting more efficacious treatments to patients faster in the pursuit of precision medicine.

Clinical & Research Tools Showcase:
Medidata Solutions

Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes.

Executing Precision Medicine in Clinical Trials
Medidata’s Rave Omics Solution brings together data, technology, and expertise to ensure that you are getting the highest return on your Omic data investment. Machine learning and AI identify sample quality issues and accelerate the initial steps of biomarker discovery (real-world examples will be shared).

 Session Abstract – PMWC 2020 Silicon Valley

The PMWC 2020 Clinical & Research Tools Showcase will provide a 15-minute time slot for selected companies in this space. The Clinical & Research Tools is a showcase for innovative technologies that are used for the analysis of genetic variation and function, helping to advance breakthroughs in genetic health, rare disease conditions on individuals of all ages, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies empower rapidly evolving genomic revolution.